Description

Product Description

Oxaliplatin (CAS 61825-94-3) is a third-generation platinum-based chemotherapeutic agent characterized by its 1,2-diaminocyclohexane (DACH) carrier ligand. Unlike first-generation platinum drugs, Oxaliplatin forms DNA adducts that inhibit replication and transcription, triggering apoptosis and cell cycle arrest in rapidly dividing cells.

In preclinical research, Oxaliplatin is employed to study:

• Formation and repair of platinum-DNA adducts.

• Cellular response to DNA damage, including apoptosis and cell cycle modulation.

• Mechanisms of drug resistance, such as enhanced nucleotide excision repair or mismatch repair pathway activity.

• Combination therapy strategies with targeted inhibitors or other cytotoxic agents.

• Molecular pathways affected by platinum-based DNA damage, including p53, p21, and caspase activation.

Supplied as a white to off-white crystalline powder with ≥99% purity, Oxaliplatin is stable under refrigerated conditions (2–8 °C) and soluble in water, DMSO, and physiological buffers. Analytical verification is performed using HPLC, MS, and NMR to ensure consistency and high purity.

Oxaliplatin’s unique DACH ligand and platinum coordination enable selective cytotoxicity and minimize cross-resistance with other platinum compounds. Its well-characterized activity profile makes it an indispensable tool for studying DNA crosslinking, cellular cytotoxicity, apoptosis, and chemotherapy resistance mechanisms in vitro and in vivo.

Product Specifications

Mechanism of Action

Oxaliplatin exerts its activity as a platinum-based chemotherapeutic agent by forming covalent DNA adducts, leading to intra- and inter-strand DNA crosslinks. These crosslinks prevent proper DNA replication and transcription, ultimately activating cell cycle checkpoints and inducing apoptosis in rapidly dividing cells.

The 1,2-diaminocyclohexane (DACH) carrier ligand contributes to enhanced cytotoxicity and reduced cross-resistance compared to earlier platinum drugs. In preclinical research, Oxaliplatin is used to study:

• DNA damage recognition and repair mechanisms.

• Cellular responses to platinum-induced cytotoxicity.

• Mechanisms of drug resistance, including nucleotide excision repair and mismatch repair pathways.

• Signaling cascades involving p53, p21, and caspases.

• Combination therapy effects with targeted inhibitors or other chemotherapeutics.

  

Side Effects

For laboratory use, follow standard safety protocols:

• Avoid inhalation, ingestion, and skin or eye contact.

• Use gloves, lab coat, and protective eyewear.

• Conduct experiments in a fume hood or well-ventilated laboratory.

• Dispose of waste according to institutional safety regulations.

Experimental effects may include DNA crosslinking, cell cycle arrest, apoptosis, and cytotoxicity in cell-based or animal models. This product is strictly for research use only.

Keywords

Oxaliplatin, CAS 61825-94-3, platinum-based chemotherapeutic, DNA crosslinking, apoptosis induction, cell cycle disruption, preclinical cancer research, cytotoxic signaling, high purity, ≥99% purity, factory peptide supplier, peptide wholesale China, China peptide manufacturer, OEM & bulk peptide production.

Shipping Guarantee

All shipments are managed with validated cold-chain logistics to maintain compound stability. Powder is sealed in moisture-proof, light-protected containers with secondary protective wrapping. Packages include tracking and insurance for worldwide delivery.

Trade Assurance

Product authenticity is guaranteed, analytically verified using HPLC, MS, and NMR. Each batch includes a Certificate of Analysis (CoA) confirming ≥99% purity. Replacement or refund is provided for any deviation from listed specifications.

Payment Support

Accepted payment options include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). Transactions are encrypted and verified for security.

Disclaimer

This product is intended for laboratory research use only. It is not for human or veterinary administration. Researchers must follow proper safety protocols. Data generated with Oxaliplatin should not be interpreted as clinical guidance or therapeutic advice.

References

1. PubChem Database: Oxaliplatin (CID 5362426)↗

2. ChEMBL Database: Oxaliplatin Bioactivity Summary (ChEMBL ID CHEMBL1327)↗

3. DrugBank: Oxaliplatin – DB00515↗

4. PubMed ID 16005386 – Oxaliplatin mechanism of DNA crosslinking and cytotoxicity↗

5. IUPHAR/BPS Guide to Pharmacology: Oxaliplatin target profile↗